Valuation: Roche Holding AG

Market Cap 267B 330B 289B 247B 468B 31,592B 477B 3,212B 1,248B 15,460B 1,239B 1,212B 53,667B P/E 2026 *
17.8x
P/E 2027 * 16.7x
Enterprise Value 278B 343B 301B 257B 486B 32,843B 496B 3,339B 1,297B 16,072B 1,288B 1,260B 55,793B EV / Sales 2026 *
4.43x
EV / Sales 2027 * 4.15x
Free-Float
88.78%
Yield 2026 *
2.99%
Yield 2027 * 3.06%
1 day+3.16%
Current month+3.61%
6 months-1.82%
Current year+1.79%
Current year 311.6
Extreme 311.6
377
1 year 221.3
Extreme 221.3
377
3 years 212.3
Extreme 212.3
377
5 years 212.3
Extreme 212.3
404.1
10 years 202.23
Extreme 202.231
404.1
Manager TitleAgeSince
Chief Executive Officer 51 14/03/2023
Director of Finance/CFO 59 05/06/2011
Chief Operating Officer - 30/09/2025
Director TitleAgeSince
Director/Board Member 68 31/12/1995
Chairman 59 14/03/2023
Director/Board Member 73 02/03/2015
Change 5-day change 1-year change 3-year change Capi.($)
+3.13%0.00% - - 330B
-1.60%+2.02%+56.34%+168.94% 1,084B
-1.44%+3.71%+69.07%+65.40% 634B
-0.75%+0.67%+33.18%+86.52% 447B
-8.36%-10.38%+25.74%+27.99% 295B
-0.51%-2.09%+28.49%+46.12% 285B
-0.93%-3.60%-27.76%-39.72% 218B
-0.03%+1.84%+23.90%+68.30% 199B
-0.40%+7.82%+22.29%+82.50% 169B
-0.08%+0.71%-6.13%-32.31% 137B
Average -0.73%+2.39%+25.01%+52.64% 385.22B
Weighted average by Cap. -0.46%+2.47%+39.52%+86.25%

Financials

2026 *2027 *
Net sales 62.64B 77.36B 67.85B 57.89B 110B 7,407B 112B 753B 293B 3,625B 291B 284B 12,583B 65.24B 80.57B 70.67B 60.29B 114B 7,715B 117B 784B 305B 3,775B 303B 296B 13,106B
Net income 15.23B 18.81B 16.49B 14.07B 26.67B 1,801B 27.21B 183B 71.13B 881B 70.62B 69.07B 3,059B 16.28B 20.1B 17.63B 15.04B 28.51B 1,925B 29.08B 196B 76.02B 942B 75.48B 73.82B 3,269B
Net Debt 10.58B 13.07B 11.46B 9.78B 18.53B 1,251B 18.91B 127B 49.43B 612B 49.08B 48B 2,126B 3.89B 4.81B 4.22B 3.6B 6.82B 460B 6.96B 46.81B 18.19B 225B 18.06B 17.66B 782B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Date Price Change Volume
09/07/26 CHF 334.01 +3.12% 295
08/07/26 CHF 323.90 0.00% 6,493
07/07/26 CHF 323.90 0.00% 1,400
06/07/26 CHF 323.90 0.00% 2,786
03/07/26 CHF 323.90 0.00% 496
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
334.90CHF
Average target price
359.22CHF
Spread / Average Target
+7.26%

Quarterly revenue - Rate of surprise